An estimated 1.5 million people in the UK are currently using weight loss injections, and more could soon access these treatments through their general practitioners if they meet specific criteria. Tirzepatide, commonly known as Mounjaro, is a medication designed to help reduce hunger by making users feel full for longer periods. According to the NHS, the drug works by mimicking gut hormones released after eating, which tricks the brain into feeling satiated and slows down the time it takes for the stomach to empty.
Results from using Mounjaro can vary depending on factors such as metabolism, how well individuals stick to their diet, and their starting weight. However, most users notice changes within the first few weeks.
Starting in March 2025, Mounjaro may be prescribed to manage weight, but only if recommended by a specialist weight management service. From this summer, the medication will become available through primary care specialists, including GPs, as reported by the Express.
The rollout will happen gradually, beginning with patients who have the highest clinical need. The programme is expected to take around three years to be fully implemented, meaning some NHS patients could become eligible as early as 2025, while others may have to wait until 2026, 2027, or even 2028 before receiving approval.
Related Topics:
Mounjaro and Ozempic Alert for Holiday Travel Insurance
Are Weight Loss Drugs Driving Customers Away from McDonald’s
